Related references
Note: Only part of the references are listed.High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis
Russell A. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies
Herbert I. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
Alicia F. C. Okines et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Thrombotic Complications of Erythropoiesis-Stimulating Agents
Giuseppe Lippi et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2010)
Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management
Mario Mandala et al.
THROMBOSIS RESEARCH (2010)
Prevention and treatment of venous thromboembolism among patients with cancer: The American Society of Clinical Oncology Guidelines
Gary H. Lyman et al.
THROMBOSIS RESEARCH (2010)
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The 'GISCAD-alternating schedule' study findings
Mario Mandala et al.
EUROPEAN JOURNAL OF CANCER (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli et al.
LANCET ONCOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Ronald M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
R. M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mechanisms of adverse effects of anti-VEGF therapy for cancer
T. Kamba et al.
BRITISH JOURNAL OF CANCER (2007)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
A. A. Khorana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic
Michael Cohenuram et al.
ANTI-CANCER DRUGS (2007)
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer
Charles L. Bennett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Mechanisms of endothelial response to oxidative aggression:: Protective role of autologous VEGF and induction of VEGFR2 by H2O2
Francisco R. Gonzalez-Pacheco et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family
I Zachary et al.
CARDIOVASCULAR RESEARCH (2001)
Share Paper
